Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

PURPOSE: NLG207 (formerly CRLX101) is a nanoparticle–drug conjugate (NDC) of the potent topoisomerase I inhibitor, camptothecin (CPT). The present study sought to characterize the complex pharmacokinetics (PK) of NLG207 and better describe CPT release from nanoparticles using a population PK (popPK)...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Keith T., Huitema, Alwin D. R., Dorlo, Thomas P. C., Peer, Cody J., Cordes, Lisa M., Sciuto, Linda, Wroblewski, Susan, Pommier, Yves, Madan, Ravi A., Thomas, Anish, Figg, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515962/
https://www.ncbi.nlm.nih.gov/pubmed/32897402
http://dx.doi.org/10.1007/s00280-020-04134-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515962/
https://www.ncbi.nlm.nih.gov/pubmed/32897402
http://dx.doi.org/10.1007/s00280-020-04134-9

Ejemplares similares